Recombinant
RabMAb

Anti-Cytokeratin 5 antibody [SP178] (ab183336)

Overview

  • Product name
    Anti-Cytokeratin 5 antibody [SP178]
    See all Cytokeratin 5 primary antibodies
  • Description
    Rabbit monoclonal [SP178] to Cytokeratin 5
  • Host species
    Rabbit
  • Tested applications
    Suitable for: Flow Cyt, IHC-Pmore details
  • Species reactivity
    Reacts with: Human
    Predicted to work with: Mouse, Rat, Cow
  • Immunogen

    Synthetic peptide within Human Cytokeratin 5 aa 50-150 (internal sequence). The exact sequence is proprietary.
    Database link: P13647

  • Positive control
    • Human prostate, breast, bladder, tonsil, skin, skin squamous cell carcinoma, rectal carcinoma, lung squamous cell carcinoma and cervix squamous cell carcinoma tissues; A431 cells.
  • General notes

    There are no definitive signs to indicate instability of this product; therefore, positive and negative controls should be tested simultaneously with unknown specimens.

    Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMab® patents

Properties

  • Form
    Liquid
  • Storage instructions
    Shipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C long term. Avoid freeze / thaw cycle.
  • Storage buffer
    pH: 7.6
    Preservative: 0.1% Sodium azide
    Constituents: 99% PBS, 1% BSA
  • Concentration information loading...
  • Purification notes
    Purified from TCS by protein A/G.
  • Clonality
    Monoclonal
  • Clone number
    SP178
  • Isotype
    IgG
  • Research areas

Applications

Our Abpromise guarantee covers the use of ab183336 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
Flow Cyt 1/100.

Incubate for 30 minutes at 4°C.

 

 

 

 

ab172730 - Rabbit monoclonal IgG, is suitable for use as an isotype control with this antibody.

 

IHC-P 1/100.

Deparaffinization:  Deparaffinize slides using xylene or xylene alternative and graded alcohols.
Antigen Retrieval:  Boil tissue section in EDTA buffer, pH 8.0 for 10 min followed by cooling at room temperature for 20 min.   
Primary Antibody Incubation:  Incubate for 10 minutes at room temperature.
Slide Washing:  Slides must be washed in between steps.  Rinse slides with PBS/0.05% Tween.

Target

  • Involvement in disease
    Defects in KRT5 are a cause of epidermolysis bullosa simplex Dowling-Meara type (DM-EBS) [MIM:131760]. DM-EBS is a severe form of intraepidermal epidermolysis bullosa characterized by generalized herpetiform blistering, milia formation, dystrophic nails, and mucous membrane involvement.
    Defects in KRT5 are the cause of epidermolysis bullosa simplex with migratory circinate erythema (EBSMCE) [MIM:609352]. EBSMCE is a form of intraepidermal epidermolysis bullosa characterized by unusual migratory circinate erythema. Skin lesions appear from birth primarily on the hands, feet, and legs but spare nails, ocular epithelia and mucosae. Lesions heal with brown pigmentation but no scarring. Electron microscopy findings are distinct from those seen in the DM-EBS, with no evidence of tonofilament clumping.
    Defects in KRT5 are a cause of epidermolysis bullosa simplex Weber-Cockayne type (WC-EBS) [MIM:131800]. WC-EBS is a form of intraepidermal epidermolysis bullosa characterized by blistering limited to palmar and plantar areas of the skin.
    Defects in KRT5 are a cause of epidermolysis bullosa simplex Koebner type (K-EBS) [MIM:131900]. K-EBS is a form of intraepidermal epidermolysis bullosa characterized by generalized skin blistering. The phenotype is not fundamentally distinct from the Dowling-Meara type, althought it is less severe.
    Defects in KRT5 are the cause of epidermolysis bullosa simplex with mottled pigmentation (MP-EBS) [MIM:131960]. MP-EBS is a form of intraepidermal epidermolysis bullosa characterized by blistering at acral sites and 'mottled' pigmentation of the trunk and proximal extremities with hyper- and hypopigmentation macules.
    Defects in KRT5 are the cause of Dowling-Degos disease (DDD) [MIM:179850]; also known as Dowling-Degos-Kitamura disease or reticulate acropigmentation of Kitamura. DDD is an autosomal dominant genodermatosis. Affected individuals develop a postpubertal reticulate hyperpigmentation that is progressive and disfiguring, and small hyperkeratotic dark brown papules that affect mainly the flexures and great skin folds. Patients usually show no abnormalities of the hair or nails.
  • Sequence similarities
    Belongs to the intermediate filament family.
  • Information by UniProt
  • Database links
  • Alternative names
    • 58 kDa cytokeratin antibody
    • CK-5 antibody
    • CK5 antibody
    • Cytokeratin-5 antibody
    • Cytokeratin5 antibody
    • DDD antibody
    • DDD1 antibody
    • EBS2 antibody
    • epidermolysis bullosa simplex 2 Dowling-Meara/Kobner/Weber-Cockayne types antibody
    • K2C5_HUMAN antibody
    • K5 antibody
    • keratin 5 (epidermolysis bullosa simplex, Dowling-Meara/Kobner/Weber-Cockayne types) antibody
    • Keratin 5 antibody
    • Keratin antibody
    • keratin complex 2, basic, gene 5 antibody
    • keratin, type II cytoskeletal 5 antibody
    • Keratin-5 antibody
    • Keratin5 antibody
    • KRT 5 antibody
    • Krt5 antibody
    • KRT5A antibody
    • type II cytoskeletal 5 antibody
    • Type-II keratin Kb5 antibody
    see all

Images

  • Immunohistochemical analysis of formalin-fixed, paraffin-embedded Human cervix squamous cell carcinoma tissue labeling Cytokeratin 5 with ab183336 at 1/100 dilution.

  • Immunohistochemical analysis of formalin-fixed, paraffin-embedded Human lung squamous cell carcinoma tissue labeling Cytokeratin 5 with ab183336 at 1/100 dilution.

  • Immunohistochemical analysis of formalin-fixed, paraffin-embedded Human skin squamous cell carcinoma tissue labeling Cytokeratin 5 with ab183336 at 1/100 dilution.

  • Immunohistochemical analysis of formalin-fixed, paraffin-embedded Human rectal carcinoma tissue labeling Cytokeratin 5 with ab183336 at 1/100 dilution.

  • Immunohistochemical analysis of formalin-fixed, paraffin-embedded Human tonsil tissue labeling Cytokeratin 5 with ab183336 at 1/100 dilution.

  • Immunohistochemical analysis of formalin-fixed, paraffin-embedded Human skin tissue labeling Cytokeratin 5 with ab183336 at 1/100 dilution.

  • Immunohistochemical analysis of formalin-fixed, paraffin-embedded Human bladder tissue labeling Cytokeratin 5 with ab183336 at 1/100 dilution.

  • Immunohistochemical analysis of formalin-fixed, paraffin-embedded Human prostate tissue labeling Cytokeratin 5 with ab183336 at 1/100 dilution.

  • Immunohistochemical analysis of formalin-fixed, paraffin-embedded Human breast tissue labeling Cytokeratin 5 with ab183336 at 1/100 dilution.

  • Flow cytometric analysis of A431 cells labeling Cytokeratin 5 with ab183336 at 1/100 dilution (green) compared to a negative control rabbit IgG (blue).

References

This product has been referenced in:
  • Anderson WC  et al. Initiation and characterization of small cell lung cancer patient-derived xenografts from ultrasound-guided transbronchial needle aspirates. PLoS One 10:e0125255 (2015). Read more (PubMed: 25955027) »

See 1 Publication for this product

Customer reviews and Q&As

Abcam has not validated the combination of species/application used in this Abreview.
Application
Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections)
Sample
Rat Tissue sections (Bladder dysplasia after chemical injury)
Antigen retrieval step
Heat mediated
Permeabilization
Yes - 0.1% Triton X-100
Specification
Bladder dysplasia after chemical injury
Blocking step
Serum as blocking agent for 1 hour(s) and 0 minute(s) · Concentration: 5% · Temperature: 25°C
Fixative
Formaldehyde
Username

Abcam user community

Verified customer

Submitted Dec 13 2016

Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"

Sign up